WuXi AppTec (OTCMKTS:WUXAY – Get Free Report) is expected to release its results after the market closes on Monday, October 26th. Analysts expect WuXi AppTec to announce earnings of $0.4377 per share and revenue of $2.39 billion for the quarter.
WuXi AppTec Trading Down 0.8%
Shares of OTCMKTS:WUXAY opened at $23.71 on Friday. WuXi AppTec has a twelve month low of $12.45 and a twelve month high of $28.69. The company’s 50 day moving average is $25.72 and its 200 day moving average is $20.84.
Analysts Set New Price Targets
Separately, Zacks Research downgraded shares of WuXi AppTec from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, WuXi AppTec currently has a consensus rating of “Moderate Buy”.
Get Our Latest Analysis on WuXi AppTec
WuXi AppTec Company Profile
WuXi AppTec is a global pharmaceutical and biotechnology services company that provides contract research, development and manufacturing services. The company supports drug developers throughout the product life cycle, from early-stage discovery and laboratory testing through clinical development and commercial production.
Its offerings include medicinal and synthetic chemistry, biology research, preclinical and clinical testing, regulatory support, pharmaceutical manufacturing, and the development and manufacturing of advanced therapies.
Featured Stories
- Five stocks we like better than WuXi AppTec
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.
